Leber’s Hereditary Optic Neuropathy – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of Leber’s hereditary optic neuropathy (LHON) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of LHON for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s LHON forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of LHON over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts three LHON patient populations, as follows:
- Diagnosed prevalent cases.
- Diagnosed prevalent cases by gene mutation.
- Drug-treatable prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Leber's Hereditary Optic Neuropathy - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of Leber's hereditary optic neuropathy)
- Diagnosed prevalent cases of Leber's hereditary optic neuropathy
- Diagnosed prevalent cases of Leber's hereditary optic neuropathy by gene mutation
- Drug-treatable prevalent cases of Leber's hereditary optic neuropathy
- Risk/protective factors applied to disease forecast models
- Reference materials
